+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients



Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients



Journal of Palliative Medicine 13(7): 815-818



Relief of adverse events induced by chemotherapy is an important issue for patients, especially those with a poor prognosis, such as with pancreatic cancer. There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor. GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260837

Download citation: RISBibTeXText

PMID: 20636150

DOI: 10.1089/jpm.2009.0404


Related references

Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain. Diseases of the Esophagus 29(4): 367-376, 2015

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value in Health 12(1): 34-39, 2009

Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology 46(7-8): 789-796, 2012

Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy. Digestion 86(4): 315-322, 2013

Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. Journal of Neurogastroenterology and Motility 19(1): 61-69, 2013

Distal esophageal reflux accompanies nocturnal gastric acid breakthrough in patients with gastroesophageal reflux disease on proton pump inhibitor bid. Gastroenterology 114(4 PART 2): A56-A57, April 15, 1998

The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--clinical overview of gastroesophageal reflux disease. Roundtable discussion. Managed Care Interface Suppl B: 13-20; Discussion 24-7, 31-3, 2001

Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease. Journal of Gastroenterology 41(3): 286-287, 2006

Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scandinavian Journal of Gastroenterology 47(7): 751-761, 2012

The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder. Digestion 89(1): 61-67, 2014

Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology 10(12): 1360-1366, 2013

Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. Clinics 66(4): 557-561, 2011

A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. Tohoku Journal of Experimental Medicine 209(3): 181-189, 2006

Weight Loss Is Truly Effective in Reducing Symptoms and Proton Pump Inhibitor Use in Patients With Gastroesophageal Reflux Disease. Clinical Gastroenterology and Hepatology 13(11): 2023-2023, 2016

The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma. Expert Opinion on PharmacoTherapy 7(15): 2015-2017, 2006